312 related articles for article (PubMed ID: 27283767)
1. Targeting BET bromodomain proteins in solid tumors.
Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Targeting of BET Proteins in Cancer.
French CA
Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
[TBL] [Abstract][Full Text] [Related]
4. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
5. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
Spriano F; Stathis A; Bertoni F
Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
[TBL] [Abstract][Full Text] [Related]
6. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
Abedin SM; Boddy CS; Munshi HG
Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
[TBL] [Abstract][Full Text] [Related]
7. BET Inhibitors as Anticancer Agents: A Patent Review.
Ali I; Choi G; Lee K
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
[TBL] [Abstract][Full Text] [Related]
8. Non-canonical transcriptional consequences of BET inhibition in cancer.
Letson C; Padron E
Pharmacol Res; 2019 Dec; 150():104508. PubMed ID: 31698067
[TBL] [Abstract][Full Text] [Related]
9. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
11. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
12. BET inhibitors in cancer therapeutics: a patent review.
Ghoshal A; Yugandhar D; Srivastava AK
Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
[TBL] [Abstract][Full Text] [Related]
13. BET Proteins as Attractive Targets for Cancer Therapeutics.
Sarnik J; Popławski T; Tokarz P
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681760
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
15. BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.
Markowski MC; De Marzo AM; Antonarakis ES
Expert Opin Investig Drugs; 2017 Dec; 26(12):1391-1397. PubMed ID: 29032717
[TBL] [Abstract][Full Text] [Related]
16. Domain-selective targeting of BET proteins in cancer and immunological diseases.
Petretich M; Demont EH; Grandi P
Curr Opin Chem Biol; 2020 Aug; 57():184-193. PubMed ID: 32741705
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of BET inhibitors in breast cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Breast; 2020 Oct; 53():152-163. PubMed ID: 32827765
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain inhibitors: what does the future hold?
Bhattacharya S; Piya S; Borthakur G
Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
[TBL] [Abstract][Full Text] [Related]
19. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
Wadhwa E; Nicolaides T
Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
[TBL] [Abstract][Full Text] [Related]
20. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.
Bechter O; Schöffski P
Pharmacol Ther; 2020 Apr; 208():107479. PubMed ID: 31931101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]